KH617

KH617 is an investigational drug developed by Sichuan Honghe Biotechnology for the treatment of glioblastoma and advanced solid tumors. Preclinical studies have shown that KH617 significantly reduces tumor growth rate and prolongs overall survival in animal models, demonstrating efficacy superior to existing therapies. The drug is administered as an injection and must be diluted with 5% dextrose injection. As of 2022, clinical trials were approved by regulatory authorities in China (NMPA) and the US (FDA), with ongoing Phase 1 studies evaluating its safety, tolerability, pharmacokinetics, dose-limiting toxicity, maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity in patients with advanced solid tumors. The precise mechanism of action has not been disclosed.